Compounding pharmacies which were barred from producing injectable GHK-Cu since 2023 can now begin preparing pharmaceutical-grade product again (effective July 2026 once advisory panel guidance is finalized)
Prevents Type 2 Diabetes Progression By improving insulin sensitivity and beta-cell function Supports Cardiovascular Health Reduces blood pressure, LDL cholesterol, and inflammation Lowers Risk of Fatty Liver Disease (NAFLD/NASH) Helps reduce liver fat accumulation Improves PCOS Symptoms Regulates ovulation, insulin resistance, and weight in women with PCOS May Benefit Neuroprotection Early studies suggest a role in reducing neuroinflammation and cognitive decline Contraindications These GLP-1s are generally well-tolerated, but some patients should not take them
A once-weekly injectable glucose-dependent insulinotropic polypeptide/GLP-1 dual agonist conferred up to 14.7% weight loss at 13 weeks for adults with overweight or obesity, according to findings from the VENTURE trial published in Obesity
Phase 3 results are expected in 2026
This medication mimics hormones that make you feel fuller and provides other benefits, such as balancing blood sugar and promoting a faster metabolism
